Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer

Marc Warmoes, Siu W. Lam, Petra van der Groep, Janneke E. Jaspers, Yvonne H C M Smolders, Leon de Boer, Thang V. Pham, Sander R. Piersma, Sven Rottenberg, Epie Boven, Jos Jonkers, Paul J. van Diest, Connie R. Jimenez

Research output: Contribution to journalArticle

Abstract

Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1-and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval [95% CI], 1.85-7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% CI, 1.08-5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.

Original languageEnglish (US)
Pages (from-to)63537-63548
Number of pages12
JournalOncotarget
Volume7
Issue number39
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Proteomics
Biomarkers
Breast Neoplasms
Mutation
Odds Ratio
Confidence Intervals
Exosomes
Phenotype
Type I DNA Topoisomerase
Proteins
Cadherins
Proteome
Tandem Mass Spectrometry
Transcriptome
Age of Onset
Logistic Models
Immunohistochemistry

Keywords

  • Biomarkers
  • BRCA1
  • Breast cancer
  • Proteomics

ASJC Scopus subject areas

  • Oncology

Cite this

Warmoes, M., Lam, S. W., van der Groep, P., Jaspers, J. E., Smolders, Y. H. C. M., Boer, L. D., ... Jimenez, C. R. (2016). Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget, 7(39), 63537-63548. https://doi.org/10.18632/oncotarget.11535

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. / Warmoes, Marc; Lam, Siu W.; van der Groep, Petra; Jaspers, Janneke E.; Smolders, Yvonne H C M; Boer, Leon de; Pham, Thang V.; Piersma, Sander R.; Rottenberg, Sven; Boven, Epie; Jonkers, Jos; van Diest, Paul J.; Jimenez, Connie R.

In: Oncotarget, Vol. 7, No. 39, 2016, p. 63537-63548.

Research output: Contribution to journalArticle

Warmoes, M, Lam, SW, van der Groep, P, Jaspers, JE, Smolders, YHCM, Boer, LD, Pham, TV, Piersma, SR, Rottenberg, S, Boven, E, Jonkers, J, van Diest, PJ & Jimenez, CR 2016, 'Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer', Oncotarget, vol. 7, no. 39, pp. 63537-63548. https://doi.org/10.18632/oncotarget.11535
Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YHCM, Boer LD et al. Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. Oncotarget. 2016;7(39):63537-63548. https://doi.org/10.18632/oncotarget.11535
Warmoes, Marc ; Lam, Siu W. ; van der Groep, Petra ; Jaspers, Janneke E. ; Smolders, Yvonne H C M ; Boer, Leon de ; Pham, Thang V. ; Piersma, Sander R. ; Rottenberg, Sven ; Boven, Epie ; Jonkers, Jos ; van Diest, Paul J. ; Jimenez, Connie R. / Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 39. pp. 63537-63548.
@article{807d03120322401f8243db325e4dfa19,
title = "Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer",
abstract = "Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1-and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95{\%} confidence interval [95{\%} CI], 1.85-7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95{\%} CI, 1.08-5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.",
keywords = "Biomarkers, BRCA1, Breast cancer, Proteomics",
author = "Marc Warmoes and Lam, {Siu W.} and {van der Groep}, Petra and Jaspers, {Janneke E.} and Smolders, {Yvonne H C M} and Boer, {Leon de} and Pham, {Thang V.} and Piersma, {Sander R.} and Sven Rottenberg and Epie Boven and Jos Jonkers and {van Diest}, {Paul J.} and Jimenez, {Connie R.}",
year = "2016",
doi = "10.18632/oncotarget.11535",
language = "English (US)",
volume = "7",
pages = "63537--63548",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "39",

}

TY - JOUR

T1 - Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer

AU - Warmoes, Marc

AU - Lam, Siu W.

AU - van der Groep, Petra

AU - Jaspers, Janneke E.

AU - Smolders, Yvonne H C M

AU - Boer, Leon de

AU - Pham, Thang V.

AU - Piersma, Sander R.

AU - Rottenberg, Sven

AU - Boven, Epie

AU - Jonkers, Jos

AU - van Diest, Paul J.

AU - Jimenez, Connie R.

PY - 2016

Y1 - 2016

N2 - Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1-and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval [95% CI], 1.85-7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% CI, 1.08-5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.

AB - Breast cancer arising in female BRCA1 mutation carriers is characterized by an aggressive phenotype and early age of onset. We performed tandem mass spectrometry-based proteomics of secretomes and exosome-like extracellular vesicles from BRCA1-deficient and BRCA1-proficient murine breast tumor models to identify extracellular protein biomarkers, which can be used as an adjunct to current diagnostic modalities in patients with BRCA1-deficient breast cancer. We identified 2,107 proteins, of which 215 were highly enriched in the BRCA1-deficient secretome. We demonstrated that BRCA1-deficient secretome proteins could cluster most human BRCA1-and BRCA2-related breast carcinomas at the transcriptome level. Topoisomerase I (TOP1) and P-cadherin (CDH3) expression was investigated by immunohistochemistry on tissue microarrays of a large panel of 253 human breast carcinomas with and without BRCA1/2 mutations. We showed that expression of TOP1 and CDH3 was significantly increased in human BRCA1-related breast carcinomas relative to sporadic cases (p = 0.002 and p < 0.001, respectively). Multiple logistic regression showed that TOP1 (adjusted odds ratio [OR] 3.75; 95% confidence interval [95% CI], 1.85-7.71, p < 0.001) as well as CDH3 positivity (adjusted OR 2.45; 95% CI, 1.08-5.49, p = 0.032) were associated with BRCA1/2-related breast carcinomas after adjustment for triple-negative phenotype and age. In conclusion, proteome profiling of secretome using murine breast tumor models is a powerful strategy to identify non-invasive candidate biomarkers of BRCA1-deficient breast cancer. We demonstrate that TOP1 and CDH3 are closely associated to BRCA1-deficient breast cancer. These data merit further investigation for early detection of tumors arising in BRCA1 mutation carriers.

KW - Biomarkers

KW - BRCA1

KW - Breast cancer

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=84994048918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994048918&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11535

DO - 10.18632/oncotarget.11535

M3 - Article

VL - 7

SP - 63537

EP - 63548

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 39

ER -